As a promising RSK inhibitor, luteolin can significantly inhibit RSK-mediated phosphorylation of YB-1, thereby inhibiting the Notch pathway to exert anti-breast cancer effects.[96]. This evidence concerns the gene YBX1 and breast cancer.